Newland Pharmaceutical Co., Ltd. (SHE:301277)
China flag China · Delayed Price · Currency is CNY
8.65
-0.22 (-2.48%)
At close: Nov 13, 2026

Newland Pharmaceutical Cash Flow Statement

Millions CNY. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Net Income
93.01121.25173.63158.98132.3114.98
Depreciation & Amortization
54.955.0737.8431.0824.2420.86
Other Amortization
2.632.472.231.540.16-
Loss (Gain) From Sale of Assets
0.47---0.070.440.21
Asset Writedown & Restructuring Costs
1.021.492.621.460.320.11
Loss (Gain) From Sale of Investments
-10.44-10.44-13.95-17.6-1.52-0.17
Provision & Write-off of Bad Debts
-0.87-0.872.27-3.62.2311.14
Other Operating Activities
-11.728.635.05-0.656.296.54
Change in Accounts Receivable
66.0366.03-82.3117.51-146.8-99.16
Change in Inventory
-32.92-32.92-18.2521.625.05-29.15
Change in Accounts Payable
-93.4-93.417.32-54.728.4520
Change in Other Net Operating Assets
-1.6-1.60.3-0.485.283.9
Operating Cash Flow
68.35116.94126.76259.4682.8549.08
Operating Cash Flow Growth
-49.44%-7.75%-51.14%213.19%68.80%2.55%

Investing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Capital Expenditures
-36.76-101.38-110.79-96.51-74.34-25.4
Sale of Property, Plant & Equipment
0.210.060.140.540.040.06
Investment in Securities
-204.55-13.9578.28129.46-691.5-8.5
Other Investing Activities
-0.26---0.330
Investing Cash Flow
-241.35-115.28-32.3633.48-765.47-33.83

Financing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Long-Term Debt Issued
----89.09118.46
Total Debt Issued
----89.09118.46
Long-Term Debt Repaid
--1.8-3.25-2.75-203.05-100
Lease Payments
-1.8-1.8-3.25-2.75-2.9-
Total Debt Repaid
-1.42-1.8-3.25-2.75-203.05-100
Net Debt Issued (Repaid)
-1.42-1.8-3.25-2.75-113.9618.46
Issuance of Common Stock
----838.574
Common Dividends Paid
-78.42-112.02-80.02-66.68-6.77-36.7
Other Financing Activities
1.46----19.09-6.94
Financing Cash Flow
-78.37-113.82-83.26-69.43698.74-21.19

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Net Cash Flow
-251.37-112.1611.14223.5116.12-5.94

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Free Cash Flow
31.5915.5515.97162.948.523.68
Free Cash Flow Growth
91.47%-2.63%-90.20%1816.39%-64.10%-23.36%
Free Cash Flow Margin
4.30%2.31%2.20%25.01%1.35%4.61%
Free Cash Flow Per Share
0.080.040.040.420.030.08
Levered Free Cash Flow
2.0522.2229.85158.98-11.33-12.63
Unlevered Free Cash Flow
2.0822.3529.91159.06-7.03-8.43
Free Cash Flow After Leases
29.7913.7512.73160.195.6123.68

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Cash Income Tax Paid
40.938.5853.7243.5966.6843.77
Change in Working Capital
-60.64-60.64-82.9388.32-81.62-104.59